Overview

Dose Proportionality Study About Amaryl M Slow Release (SR) 1/500 mg

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The pharmacokinetics of glimepiride and metformin will be compared after single dose intake of both combinations in order to answer to the following questions: - Is there a dose proportionality effect between Amaryl M SR 1/500 mg and Amaryl M SR 2/500 mg? - What is the safety profile of Amaryl M SR 1/500 mg and Amaryl M SR 2/500 mg?
Phase:
Phase 1
Details
Lead Sponsor:
Handok Inc.
Handok Pharmaceuticals Co., Ltd.
Treatments:
Glimepiride
Metformin